- In March 2024, Boehringer Ingelheim, a prominent player in the animal health industry, partnered with Square Pharmaceuticals to introduce Aftovaxpur in Bangladesh. This innovative vaccine is designed to combat foot-and-mouth disease (FMD) in ruminants, such as cattle and sheep. The launch aims to improve livestock health and bolster the agricultural sector in the region
- In April 2023, scientists at Cornell University's College of Veterinary Medicine (CVM) developed a novel diagnostic test for identifying Brucella canis. This innovative test enables early diagnosis of the zoonotic disease, which can be transmitted to humans through contact with infected dogs. As a result, this advancement is expected to promote increased vaccination efforts over time
- In April 2022, Ceva Santé Animale and Mitsui & Co., Ltd. formed a joint venture to expand veterinary laboratory capabilities in Japan. This collaboration aims to tackle the challenges related to animal diseases and food safety within the country. As a result, this initiative is anticipated to significantly contribute to market growth by enhancing disease management and ensuring safer food production practices
- In September 2020, Hester Biosciences announced an agreement to acquire indigenous technology from ICAR-IVRI (Indian Council of Agricultural Research - Indian Veterinary Research Institute) for developing the Brucella Abortus S19 Delta Per vaccine. This strategic move enabled the company to expand its product portfolio and enhance its offerings in the veterinary vaccine market. Consequently, it is expected to boost revenue generation and strengthen Hester Biosciences' position in the industry
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Medication and Others), Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Brucellosis Market size was valued at USD 276.43 USD Million in 2023.
The Global Brucellosis Market is projected to grow at a CAGR of 4.5% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
